Business

Commercial launch of low priced COVID-19 test approved by DGCI

The Drugs Controller General of India has approved the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) has said.

migrator

New Delhi

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement. The test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use. CRISPR is a genome editing technology to diagnose diseases. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology). 

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Also Read

TVK MLA bribery case: AIADMK leader Mannan appears before Madurai CCB police

Tamil Nadu’s bonded labour cases collapse over weak evidence

Shami retires from Test cricket, to continue playing white-ball formats

Production of Tesla's Cybertruck will wind down soon with allure escaping most potential buyers

US election confirms erosion of support for Israel, with even Trump questioning military aid

SCROLL FOR NEXT